Continued growth in the development of large molecule therapeutics has constrained resources for in vivo studies and in vitro sample analysis. In addition, the COVID-19 pandemic has brought renewed urgency to vaccine research and development, emphasizing a need to protect the world against existing, re-emerging and emerging pathogens and accelerate …
PK, PD and immunogenicity assays to support clinical trials – building the bigger picture
Understanding how a body processes a therapy and a therapy’s effect on the body is a critical step for understanding safety and efficacy to support clinical trials. But the process of characterization differs between small-molecule therapies and biotherapeutics. Associate Director of Early Scientific Engagement at Labcorp Drug Development, Robert Nelson, …
Non-GLP sample analysis for ocular biodistribution studies
Traditional bioanalytical service providers are geared toward analyzing large sets of samples under various regulatory guidelines, such as large nonclinical and clinical studies, which are heavily regulated. This puts a heavy burden on these service providers, creating long lead times, resource constraints and lack of flexibility. Currently, many bioanalytical laboratories …
Welcome to the digital future of pathology
Imagine getting a phone call in the middle of your study from a scientist who is seeing something completely unexpected in your study results. You need to make a decision on how to move forward and you need to do it quickly. You don’t have time to wait for a …
Application of decentralized clinical trials on AI-focused dermatology
Leveraging AI-focused dermatology in decentralized clinical trials The use of virtual tools and telecommunications skyrocketed during the COVID-19 pandemic as the world adjusted to new ways of working. In the clinical trials sector, this propelled an increasing adaptation to the decentralized clinical trial (DCT) approach to support research and minimize …
The evolution of Central Laboratory planning and forecasting to enable more efficient study delivery
Fostering trust with customers starts with delivering study materials on time, underscoring the importance of planning and forecasting processes to meet current demands. While the pandemic highlighted the need to adjust approaches and address the industry’s supply chain disruptions, it also brought forth enhanced planning and forecasting methods at Labcorp. …
NHS England’s Rare Disease Action Plan: Renewed focus on access to innovative drugs
In England, February 2022 has seen the lifting of all COVID-19 restrictions. As we cautiously enter a “new normal” after the disruption caused by the pandemic, there is renewed focus on previous healthcare priorities. The development and commercialization of innovative treatments for rare diseases has long been an area of …
Cell & Gene Therapy Answers: Preclinical oncology
Your source for answers on how to assess the preclinical efficacy of cell therapies. Watch the video > As the landscape of cell therapy continues to evolve, so are the tools to assess the efficacy of cell therapy in the preclinical space. To better understand Labcorp’s preclinical oncology role in …
Advancing inhalation toxicology capabilities to support chemical testing
Respiratory exposure to chemicals or agrochemicals poses potential risk to human health, especially to workers handling these products. Whether preparing a solution, dusting or spraying crops, or cleaning equipment, opportunities for inadvertent inhalation is a risk that can potentially lead to toxic effects, both acute and chronic. That’s why identifying …
Eight instrument considerations in flow cytometry
Whether it’s developing fit-for-purpose, customized flow assays, or optimizing the most appropriate off-the-shelf assay, the Labcorp Central Laboratory Services flow cytometry specialty testing team generates high-quality, clinically relevant and actionable data for your drug development programs. Here, we discuss how we choose our flow cytometry instruments to execute multi-site operations …